Articles In Press                   Back to the articles list | Back to browse issues page

Ethics code: IR.KUMS.MED.REC.1403.069

XML Print


1- Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran
2- Department of Anatomical Sciences, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
3- Department of Anatomical Sciences, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran , iraj.rashidi@kums.ac.ir
Abstract:   (20 Views)
Background and Objectives: Parkinson’s disease is a progressive neurodegenerative disorder characterized by dopaminergic neuronal loss and neuroinflammation. Current therapies are mostly symptomatic, necessitating novel neuroprotective strategies. Natural products rich in antioxidants and anti-inflammatory compounds have gained increasing attention. Allium ampeloprasum (wild leek), a member of the Allium family, is traditionally consumed for its medicinal properties, but its potential in Parkinson’s disease remains underexplored. This study investigated the neuroprotective and anti-inflammatory effects of A. ampeloprasum hydroalcoholic extract against 6-hydroxydopamine (6-OHDA)-induced cytotoxicity, apoptosis, mitochondrial dysfunction, and CXCR4 signaling in PC12 cells.
Materials and Methods: PC12 cells were exposed to 6-OHDA alone or in combination with A. ampeloprasum extract. Cell viability, mitochondrial membrane potential, apoptosis, CXCR4 protein and gene expression, nitric oxide (NO) production, and inflammatory mediators (PGE2 and TNF-α) were assessed using standard biochemical and molecular assays.
Results: 6-OHDA significantly reduced cell viability, disrupted mitochondrial membrane potential, and enhanced apoptosis and CXCR4 expression. Co-treatment with A. ampeloprasum extract markedly improved cell survival, restored mitochondrial function, reduced apoptosis, and downregulated CXCR4 expression (p < 0.05). Furthermore, the extract suppressed NO production and decreased PGE2 and TNF-α levels in macrophages compared to 6-OHDA treatment alone.
Conclusion: A. ampeloprasum extract exerts potent neuroprotective and anti-inflammatory effects by modulating oxidative stress, mitochondrial function, and CXCR4 signaling. These findings highlight its therapeutic potential as an adjunctive agent for Parkinson’s disease and other neurodegenerative disorders. Further in vivo and clinical studies are warranted.
 
     
Type of Study: Original Research Article | Subject: Life Science
Received: 2025/09/23 | Accepted: 2026/11/17

References
1. Parkinson J. An essay on the shaking palsy. Sherwood, Neely, and Jones; 1817.
2. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron. 2003;39(6):889-909. [DOI:10.1016/S0896-6273(03)00568-3] [PMID] [PMCID]
3. Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386(9996):896-912. [DOI:10.1016/S0140-6736(14)61393-3] [PMID]
4. Obeso JA, Stamelou M, Goetz CG, Poewe W, Lang AE, Weintraub D, et al. Past, present, and future of Parkinson's disease: a special essay on the 200th anniversary of the shaking palsy. Mov Disord. 2017;32(9):1264-310. [DOI:10.1002/mds.27115] [PMID]
5. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet. 2009;373(9680):2055-66. [DOI:10.1016/S0140-6736(09)60492-X] [PMID]
6. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology. 2009;72(21 Suppl 4):S1-136. [DOI:10.1212/WNL.0b013e3181a1d44c]
7. Schapira AH. Mitochondrial pathology in Parkinson's disease. Mt Sinai J Med. 2011;78(6):872-81. [DOI:10.1002/msj.20303] [PMID]
8. Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol. 2008;4(11):600-9. [DOI:10.1038/ncpneuro0924] [PMID]
9. Dias V, Junn E, Mouradian MM. The role of oxidative stress in Parkinson's disease. J Parkinsons Dis. 2013;3(4):461-91. [DOI:10.3233/JPD-130230] [PMID]
10. Bose A, Beal MF. Mitochondrial dysfunction in Parkinson's disease. J Neurochem. 2016;139 Suppl 1:216-31. [DOI:10.1111/jnc.13731] [PMID]
11. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 2009;8(4):382-97. [DOI:10.1016/S1474-4422(09)70062-6] [PMID]
12. Tansey MG, Goldberg MS. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis. 2010;37(3):510-8. [DOI:10.1016/j.nbd.2009.11.004] [PMID]
13. Shimoji M, Pagan F, Healey J, Sanchez-Ramos J. CXCR4 and CXCL12 expression is increased in Parkinson's disease brain. Acta Neuropathol. 2009;118(6):647-58.
14. Miller RJ, Banisadr G, Bhattacharyya BJ. CXCR4 signaling in the regulation of stem cell migration and development. J Neuroimmunol. 2008;198(1-2):31-8. [DOI:10.1016/j.jneuroim.2008.04.008] [PMID] [PMCID]
15. Guyon A. CXCL12 chemokine and its receptors as major players in the interactions between immune and nervous systems. Front Cell Neurosci. 2014;8:65. [DOI:10.3389/fncel.2014.00065] [PMID] [PMCID]
16. Iciek M, Kwiecień I, Włodek L. Biological properties of garlic and garlic-derived organosulfur compounds. Environ Mol Mutagen. 2009;50(3):247-65. [DOI:10.1002/em.20474] [PMID]
17. Corzo-Martínez M, Corzo N, Villamiel M. Biological properties of onions and garlic. Trends Food Sci Technol. 2007;18(12):609-25. [DOI:10.1016/j.tifs.2007.07.011]
18. Lanzotti V. The analysis of onion and garlic. J Chromatogr A. 2006;1112(1-2):3-22. [DOI:10.1016/j.chroma.2005.12.016] [PMID]

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.